Best Practices for Technical Reproducibility Assessment of Multiplex Immunofluorescence.
Best Practices for Technical Reproducibility Assessment of Multiplex Immunofluorescence.
复制标题
DOI：
10.3389/fmolb.2021.660202
复制
发表时间：
2021
影响因子：
5
通讯作者：
Parra ER
中科院分区：
文献类型：
--
作者：
Laberiano-Fernández C;Hernández-Ruiz S;Rojas F;Parra ER
多重免疫荧光（mIF）酪胺信号放大是一种新的和有用的工具，用于癌症的研究，它结合了在一个单一的载玻片上的多个标记物的染色。一些技术要求对于执行高质量的染色和分析以及获得结果的高内部和外部再现性是重要的。本综述手稿旨在描述mIF样本组的工作流程，并讨论确保mIF样本组具有最高重现性的挑战和解决方案。尽管该平台在癌症研究中显示出高度的灵活性，但它在分析前、分析后和分析后评估以及外部比较方面存在一些挑战。充分的抗体选择、抗体优化和验证、样本组设计、染色优化和验证、分析策略和正确的数据生成对于重现性非常重要，并且对于最大限度地减少或识别mIF染色过程中有时不完全在我们控制下的可能问题（例如组织固定过程、储存和切割程序）非常重要。
Multiplex immunofluorescence (mIF) tyramide signal amplification is a new and useful tool for the study of cancer that combines the staining of multiple markers in a single slide. Several technical requirements are important to performing high-quality staining and analysis and to obtaining high internal and external reproducibility of the results. This review manuscript aimed to describe the mIF panel workflow and discuss the challenges and solutions for ensuring that mIF panels have the highest reproducibility possible. Although this platform has shown high flexibility in cancer studies, it presents several challenges in pre-analytic, analytic, and post-analytic evaluation, as well as with external comparisons. Adequate antibody selection, antibody optimization and validation, panel design, staining optimization and validation, analysis strategies, and correct data generation are important for reproducibility and to minimize or identify possible issues during the mIF staining process that sometimes are not completely under our control, such as the tissue fixation process, storage, and cutting procedures.
登录
查看更多内容
DOI：
10.1158/1078-0432.ccr-21-2051
发表时间：
2021-09-15
期刊：
Clinical cancer research : an official journal of the American Association for Cancer Research
影响因子：
--
作者：
通讯作者：
--
影响因子：
2
作者：
Barua S;Solis L;Parra ER;Uraoka N;Jiang M;Wang H;Rodriguez-Canales J;Wistuba I;Maitra A;Sen S;Rao A
通讯作者：
Rao A
影响因子：
10.9
作者：
Giraldo NA;Nguyen P;Engle EL;Kaunitz GJ;Cottrell TR;Berry S;Green B;Soni A;Cuda JD;Stein JE;Sunshine JC;Succaria F;Xu H;Ogurtsova A;Danilova L;Church CD;Miller NJ;Fling S;Lundgren L;Ramchurren N;Yearley JH;Lipson EJ;Cheever M;Anders RA;Nghiem PT;Topalian SL;Taube JM
通讯作者：
Taube JM
影响因子：
64.8
作者：
Ghandi, Mahmoud;Huang, Franklin W.;Sellers, William R.
通讯作者：
Sellers, William R.
DOI：
10.1007/978-1-4939-9773-2_22
发表时间：
2020-01-01
期刊：
BIOMARKERS FOR IMMUNOTHERAPY OF CANCER: METHODS AND PROTOCOLS
影响因子：
--
作者：
Francisco-Cruz, Alejandro;Parra, Edwin Roger;Wistuba, Ignacio I.
通讯作者：
Wistuba, Ignacio I.